Aveva Drug Delivery Systems, Inc, Tamarac, FL
Is Aveva Drug Delivery Systems, Inc an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Aveva Drug Delivery Systems, Inc in Tamarac, FL, first registered Nov 4, 2024 and most recently registered Nov 3, 2026. FDA lists it as not yet inspected.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Tamarac, FL
- Initial registration
- Nov 4, 2024
- Most recent registration
- Nov 3, 2026
- Last inspection
- Not yet inspected
- Form 483 issued at last inspection
- N/A
- Recall after last inspection
- N/A
- Action on last inspection
- N/A
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
The dashboard does list AVEVA Drug Delivery Systems, Inc., Miramar, FL (FEI 1000307689): same name and state, different city, so not treated as this site.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Aveva Drug Delivery Systems, Inc). That is not a finding beyond this index’s search.
The Aveva Drug Delivery Systems, Inc pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
Records last pulled Nov 15, 2026. Every entry links to the original public record.